당뇨병성 족부궤양 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료법별, 궤양 유형별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Diabetic Foot Ulcer Treatment Market Size, Share & Trends Analysis Report By Treatment (Biologics, Therapy Devices), By Ulcer Type (Ischemic, Neuropathic), By End-use (Hospitals, ASCs), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,242,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,627,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,398,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

당뇨병성 족부궤양 치료제 시장의 성장과 동향:

세계 당뇨병성 족부궤양 치료제 시장 규모는 2024-2030년 동안 CAGR 6.0%를 기록하며 2030년까지 77억 6,000만 달러에 달할 것으로 예상됩니다.

당뇨병은 이 지역에서 절단, 실명, 뇌졸중, 말기신부전, 신부전, 심장마비의 주요 원인 중 하나입니다. 국제당뇨병연맹에 따르면, 2017년 유럽에서 약 6,600만 명이 당뇨병을 앓고 있습니다. 이 수치는 2045년까지 8,100만 명으로 증가할 것으로 예상되며, DFU 관련 사망률은 첫 12개월 동안 -5%, 5년 후에는 42%까지 상승할 것으로 예상됩니다.

비수술적 데브리드만제, 드레싱제, 외용제, 산소요법, 음압상처치료, 세포생물제제, 인간성장인자, 에너지요법, 전신요법 등 많은 보조요법이 DFU를 효과적으로 개선하고 치유하는 것으로 알려져 있습니다. 최근 연구에 따르면 유해한 단백질 분해 효소인 MMP-9 효소를 억제하면 상처가 더 빨리 치유될 수 있다고 합니다. 좌식 생활습관, 의료에 대한 낮은 GDP 지출, 건강에 해로운 식습관, 아시아 지역의 열악한 상환 시나리오는 이 지역에서 당뇨병의 높은 성장 요인입니다. 따라서 아시아 지역에서 DFU의 많은 폐해가 관찰되고 있습니다.

생물학적 제제 부문은 2023년 가장 큰 매출 점유율을 차지하며 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다. 생물학적 제제에는 성장인자[혈관내피성장인자(VEGF), 혈소판유래성장인자(PDGF) 등], 줄기세포, 기타 항당뇨병제 등이 포함됩니다. 이러한 약물은 고혈당을 완화하고, 산소 공급과 순환을 증가시키며, 손실된 조직을 복구하는 데 도움이 됩니다. 따라서 다양한 단계의 상처 관리에 점점 더 많이 사용되고 있으며 DFU 치료에 이상적인 것으로 간주됩니다. 상처 치료용 드레싱 재료는 2021년 매출 점유율 2위를 차지했으며, 치료용 장치와 항생제 제제가 그 뒤를 이었습니다.

시장 선도 기업들은 DFU 치유 기간을 단축하기 위해 지속적으로 새롭고 개선된 제품을 개발하고 있으며, ConvaTec, Inc, Acelity L.P. Inc, 3M Healthcare, Coloplast Corp, Smith & Nephew Plc. 등이 있습니다. COVID-19 사태에도 불구하고 이들 기업은 COVID-19 감염으로 인한 당뇨병 환자의 합병증 증가로 인해 상처 관리 제품에 대한 수요가 증가했다고 보고하고 있으며, COVID-19 치료를 받은 환자들이 당뇨병 발병으로 이어지는 당 수치 상승을 당뇨병 발병으로 이어지는 당 수치 상승을 목격하고 있기 때문에 2021년에는 시장이 안정된 속도로 성장한다고 합니다. 예를 들어, 2020년 이탈리아의 경우, COVID-19 치료를 받은 전체 당뇨병 환자 중 5%-30%가 당뇨병을 앓고 있는 것으로 나타났습니다. 또한 Smith and Nephew는 새로 출시된 상처 치유 제품 PICO 7의 매출이 2020년에 100만 명을 돌파할 것이라고 보고했습니다. 따라서 시장은 2020년에 급격하게 성장하고, 시장 추정 및 예측 기간 동안 안정될 것으로 예상됩니다.

당뇨병성 족부궤양 치료 시장 보고서 하이라이트

• 치료법별로는 상처 치유 시간 단축과 혈소판 형성 효율 향상으로 인해 생물학적 제제 분야가 2023년 가장 큰 매출 점유율을 차지했습니다.
• 궤양 유형별로는 신경허혈성 궤양 부문이 2023년 압도적인 매출 점유율을 차지했습니다.
• 병원 최종 용도별 부문은 치료 채택률 증가와 숙련된 직원 증가로 인해 2023년 두 번째 매출 점유율을 차지했습니다.
• 북미는 시장 기업의 존재와 치료 비용 및 상환 시나리오의 개선으로 인해 2023년에 가장 큰 수익 점유율을 차지했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 당뇨병성 족부궤양 치료 시장 변수·동향

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인의 영향 분석
  • 시장 성장 억제요인의 영향 분석
• 업계 분석 툴
  • Porters 분석
  • 거시경제 분석
• COVID-19의 영향 분석
  • 팬데믹 후 시장 인사이트
• 공급망 분석

제4장 당뇨병성 족부궤양 치료 시장 : 치료법 분석

• 치료법 변동 분석·시장 점유율, 2022-2030년
• 치료법별
• 시장 규모와 예측, 동향 분석, 2018-2030년
  • 창상관리 붕대
  • 생물학적 제제
  • 치료 기기
  • 항생제
  • 기타

제5장 당뇨병성 족부궤양 치료 시장 : 유형 분석

• 유형 변동 분석·시장 점유율, 2022-2030년
• 유형별
• 시장 규모와 예측, 동향 분석, 2018-2030년
  • 신경병증성 궤양
  • 허혈성 궤양
  • 신경허혈성 궤양

제6장 당뇨병성 족부궤양 치료 시장 : 최종 용도 분석

• 최종 용도 변동 분석·시장 점유율, 2022-2030년
• 최종 용도별
• 시장 규모와 예측, 동향 분석, 2018-2030년
  • 병원
  • 외래 수술 센터
  • 홈케어

제7장 당뇨병성 족부궤양 치료 시장 : 지역 추정·동향 분석

• 당뇨병성 족부궤양 치료 시장 : 지역별 전망
• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 스웨덴
  • 덴마크
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 분석

• 기업 분류
• 참여자 개요
• 재무 실적
• 제품 벤치마크
• 기업의 시장 점유율 분석, 2023년
• 기업의 시장 포지션 분석
• 전략 매핑
  • 인수합병
  • 신제품 발매
  • 파트너십과 협업
  • 확대
  • 기타
• 기업 개요
  • ConvaTec, Group Plc
  • Acelity LP, Inc.
  • 3M Health Care
  • Coloplast Corp.
  • Smith & Nephew Plc
  • B. Braun Melsungen AG
  • Medline Industries, LP.
  • Molnlycke Health Care AB
  • Medtronic Plc

제9장 애널리스트의 견해

ksm

영문 목차

영문목차

Diabetic Foot Ulcer Treatment Market Growth & Trends:

The global diabetic foot ulcer treatment market size is expected to reach USD 7.76 billion by 2030, registering a CAGR of 6.0% from 2024 to 2030, according to a new report by Grand View Research, Inc. Diabetes is one of the major causes of amputation, blindness, stroke, end-stage renal failure, kidney failure, and heart attacks in this region. According to the International Diabetes Federation, ~66 million people were suffering from diabetes in Europe in 2017. The number is expected to increase to ~81 million by 2045. The mortality rate associated with DFU is ~5% in the first 12 months and increases up to 42% by the end of 5 years.

Many adjuvant therapies such as nonsurgical debridement agents, dressings and topical agents, oxygen therapies, negative pressure wound therapy, acellular bioproducts, human growth factors, energy-based therapies, and systemic therapies are said to effectively improve and cure DFU. Recent studies suggest that the inhibition of detrimental proteinase MMP-9 enzyme allows the body to heal the wound at a quicker rate. Sedentary lifestyle, poor GDP expenditure on healthcare, unhealthy food habits, and poor reimbursement scenarios in the Asian region are the factors responsible for the high growth of diabetes in this region. Hence, numerous ill effects of DFU are observed in the Asian region.

The biologics segment held the largest revenue share in 2023 and is expected to grow at the highest rate during the forecast period. Biologics include growth factors [such as Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF)], stem cells, and other anti-diabetic drugs. These agents help reduce hyperglycemia, increase oxygenation and circulation, and repair lost tissues. Therefore, they are increasingly being used for the management of wounds in different stages and are considered to be ideal for DFU treatment. Wound care dressings held the second-largest revenue share in 2021, followed by therapy devices and antibiotic medications.

Market players are constantly developing new and improved products to ensure quicker healing time for DFU. Companies like ConvaTec, Inc.; Acelity L.P. Inc.; 3M Healthcare; Coloplast Corp.; and Smith & Nephew Plc. are among the leaders in this market. Despite the COVID-19 outbreak, these players reported an increase in demand for their wound management products due to the increased complications of diabetic patients suffering from COVID-19 infection. The market was said to increase at a steady rate in 2021 as COVID-19 treated patients witnessed a rise in sugar levels leading to the onset of diabetes. For instance, the overall proportion of diabetic patients with COVID-19 ranged from 5% - 30% in Italy in 2020. Further, Smith and Nephew reported the sales of its newly launched wound healing product, PICO 7, to cross the 1 million mark in 2020. Hence, the market grew dramatically in 2020 and is estimated to stabilize during the forecast period.

Diabetic Foot Ulcer Treatment Market Report Highlights:

• By treatment, the biologics segment captured the largest revenue share in 2023 owing to its reduced wound healing time and increased platelet formation efficiency
• Based on ulcer type, the neuro-ischemic ulcers segment held the dominant revenue share in 2023
• The hospitals end-use segment accounted for the second-largest revenue share in 2023 due to the increased adoption rate of treatment and highly experienced staff
• North America grabbed the largest revenue share in 2023 due to the presence of market players and improved treatment cost and reimbursement scenario

Table of Contents

Chapter 1 Methodology And Scope

• 1.1 Market Segmentation
• 1.2 Market Definition
• 1.3 Research Methodology
• 1.4 Information Procurement
  • 1.4.1 Purchased Database
  • 1.4.2 Gvr's Internal Database
  • 1.4.3 Secondary Sources
  • 1.4.4 Primary Research
• 1.5 Information Or Data Analysis
  • 1.5.1 Data Analysis Models
• 1.6 Market Formulation & Validation
• 1.7 Model Details
  • 1.7.1 Commodity Flow Analysis
• 1.8 List Of Secondary Sources
• 1.9 List Of Abbreviations
• 1.10 Objectives
  • 1.10.1 Objective 1
  • 1.10.2 Objective 2
  • 1.10.3 Objective 3

Chapter 2 Executive Summary

• 2.1 Market Snapshot (Regional)
• 2.2 Segment Snapshot (Treatment And Type)
• 2.3 Segment Snapshot (End-Use)
• 2.4 Competitive Landscape

Chapter 3 Diabetic Foot Ulcer Treatment Market Variables And Trends

• 3.1 Market Lineage Outlook
• 3.2 Market Dynamics
  • 3.2.1 Market Driver Impact Analysis
    • 3.2.1.1 Growing Prevalence Of Diabetes
    • 3.2.1.2 Rising Geriatric Population
    • 3.2.1.3 Increasing Government Initiative
  • 3.2.2 Market Restraint Impact Analysis
    • 3.2.2.1 High Cost Of Treatment
• 3.3 Industry Analysis Tools
  • 3.3.1 Porter's Analysis
  • 3.3.2 Macroeconomic Analysis
• 3.4 Covid-19 Impact Analysis
  • 3.4.1 Post-Pandemic Market Insights
• 3.5 Supply Chain Analysis

Chapter 4 Diabetic Foot Ulcer Treatment Market: Treatment Analysis

• 4.1 Treatment Movement Analysis & Market Share, 2022 & 2030
• 4.2 Diabetic Foot Ulcer Treatment Market Estimates & Forecast, By Treatment (USD Million)
• 4.3 Market Size & Forecasts And Trend Analysis, 2018 To 2030
  • 4.3.1 Wound Care Dressings
    • 4.3.1.1 Wound Care Dressings Market, 2018 - 2030 (USD Million)
    • 4.3.1.2 Alginate Dressings
    • 4.3.1.2.1 Alginate Dressings Market, 2018 - 2030 (USD Million)
    • 4.3.1.3 Hydrofiber Dressings
    • 4.3.1.3.1 Hydrofiber Dressings Market, 2018 - 2030 (USD Million)
    • 4.3.1.4 Foam Dressings
    • 4.3.1.4.1 Foam Dressings Market, 2018 - 2030 (USD Million)
    • 4.3.1.5 Film Dressing
    • 4.3.1.5.1 Film Dressing Market, 2018 - 2030 (USD Million)
    • 4.3.1.6 Hydrocolloid Dressings
    • 4.3.1.6.1 Hydrocolloid Dressings Market, 2018 - 2030 (USD Million)
    • 4.3.1.7 Surgical Dressings
    • 4.3.1.7.1 Surgical Dressings Market, 2018 - 2030 (USD Million)
    • 4.3.1.8 Hydrogel Dressings
    • 4.3.1.8.1 Hydrogel Dressings Market, 2018 - 2030 (USD Million)
  • 4.3.2 Biologics
    • 4.3.2.1 Biologics Market, 2018 - 2030 (USD Million)
    • 4.3.2.2 Growth Factors
    • 4.3.2.2.1 Growth Factors Market, 2018 - 2030 (USD Million)
    • 4.3.2.3 Skin Grafts
    • 4.3.2.3.1 Skin Grafts Market, 2018 - 2030 (USD Million)
  • 4.3.3 Therapy Devices
    • 4.3.3.1 Therapy Devices Market, 2018 - 2030 (USD Million)
    • 4.3.3.2 Negative Pressure Wound Therapy
    • 4.3.3.2.1 Negative Pressure Wound Therapy Market, 2018 - 2030 (USD Million)
    • 4.3.3.3 Ultrasound Therapy
    • 4.3.3.3.1 Ultrasound Therapy Market, 2018 - 2030 (USD Million)
  • 4.3.4 Antibiotic Medications
    • 4.3.4.1 Antibiotic Medications Market, 2018 - 2030 (USD Million)
  • 4.3.5 Others
    • 4.3.5.1 Others Market, 2018 - 2030 (USD Million)

Chapter 5 Diabetic Foot Ulcer Treatment Market: Type Analysis

• 5.1 Type Movement Analysis & Market Share, 2022 & 2030
• 5.2 Diabetic Foot Ulcer Treatment Market Estimates & Forecast, By Type (USD Million)
• 5.3 Market Size & Forecasts And Trend Analysis, 2018 To 2030
  • 5.3.1 Neuropathic Ulcers
    • 5.3.1.1 Neuropathic Ulcers Market, 2018 - 2030 (USD Million)
  • 5.3.2 Ischemic Ulcers
    • 5.3.2.1 Ischemic Ulcers Market, 2018 - 2030 (USD Million)
  • 5.3.3 Neuro-Ischemic Ulcers
    • 5.3.3.1 Neuro-Ischemic Ulcers Market, 2018 - 2030 (USD Million)

Chapter 6 Diabetic Foot Ulcer Treatment Market: End-Use Analysis

• 6.1 End-Use Movement Analysis & Market Share, 2022 & 2030
• 6.2 Diabetic Foot Ulcer Treatment Market Estimates & Forecast, By End-Use (USD Million)
• 6.3 Market Size & Forecasts And Trend Analysis, 2018 To 2030
  • 6.3.1 Hospitals
    • 6.3.1.1 Hospitals Market, 2018 - 2030 (USD Million)
  • 6.3.2 Ambulatory Surgical Centers
    • 6.3.2.1 Ambulatory Surgical Centers Market, 2018 - 2030 (USD Million)
  • 6.3.3 Homecare
    • 6.3.3.1 Homecare Market, 2018 - 2030 (USD Million)

Chapter 7 Diabetic Foot Ulcer Treatment Market: Regional Estimates & Trend Analysis

• 7.1 Diabetic Foot Ulcer Treatment Market: Regional Outlook
• 7.2 North America
  • 7.2.1 North America Diabetic Foot Ulcer Treatment Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2 U.S.
    • 7.2.2.1 Key Country Dynamics
    • 7.2.2.2 Competitive Scenario
    • 7.2.2.3 Regulatory Framework
    • 7.2.2.4 Reimbursement Scenario
    • 7.2.2.5 U.S. Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.2.3 Canada
    • 7.2.3.1 Key Country Dynamics
    • 7.2.3.2 Competitive Scenario
    • 7.2.3.3 Regulatory Framework
    • 7.2.3.4 Reimbursement Scenario
    • 7.2.3.5 Canada Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.3 Europe
  • 7.3.1 Europe Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2 U.K
    • 7.3.2.1 Key Country Dynamics
    • 7.3.2.2 Competitive Scenario
    • 7.3.2.3 Regulatory Framework
    • 7.3.2.4 Reimbursement Scenario
    • 7.3.2.5 U.K Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3 Germany
    • 7.3.3.1 Key Country Dynamics
    • 7.3.3.2 Competitive Scenario
    • 7.3.3.3 Regulatory Framework
    • 7.3.3.4 Reimbursement Scenario
    • 7.3.3.5 Germany Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4 France
    • 7.3.4.1 Key Country Dynamics
    • 7.3.4.2 Competitive Scenario
    • 7.3.4.3 Regulatory Framework
    • 7.3.4.4 Reimbursement Scenario
    • 7.3.4.5 France Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3.5 Italy
    • 7.3.5.1 Key Country Dynamics
    • 7.3.5.2 Competitive Scenario
    • 7.3.5.3 Regulatory Framework
    • 7.3.5.4 Reimbursement Scenario
    • 7.3.5.5 Italy Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3.6 Spain
    • 7.3.6.1 Key Country Dynamics
    • 7.3.6.2 Competitive Scenario
    • 7.3.6.3 Regulatory Framework
    • 7.3.6.4 Reimbursement Scenario
    • 7.3.6.5 Spain Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3.7 Sweden
    • 7.3.7.1 Key Country Dynamics
    • 7.3.7.2 Competitive Scenario
    • 7.3.7.3 Regulatory Framework
    • 7.3.7.4 Reimbursement Scenario
    • 7.3.7.5 Sweden Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3.8 Denmark
    • 7.3.8.1 Key Country Dynamics
    • 7.3.8.2 Competitive Scenario
    • 7.3.8.3 Regulatory Framework
    • 7.3.8.4 Reimbursement Scenario
    • 7.3.8.5 Denmark Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3.9 Norway
    • 7.3.9.1 Key Country Dynamics
    • 7.3.9.2 Competitive Scenario
    • 7.3.9.3 Regulatory Framework
    • 7.3.9.4 Reimbursement Scenario
    • 7.3.9.5 Norway Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.4 Asia Pacific
  • 7.4.1 Asia Pacific Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2 Japan
    • 7.4.2.1 Key Country Dynamics
    • 7.4.2.2 Competitive Scenario
    • 7.4.2.3 Regulatory Framework
    • 7.4.2.4 Reimbursement Scenario
    • 7.4.2.5 Japan Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3 China
    • 7.4.3.1 Key Country Dynamics
    • 7.4.3.2 Competitive Scenario
    • 7.4.3.3 Regulatory Framework
    • 7.4.3.4 Reimbursement Scenario
    • 7.4.3.5 China Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4 India
    • 7.4.4.1 Key Country Dynamics
    • 7.4.4.2 Competitive Scenario
    • 7.4.4.3 Regulatory Framework
    • 7.4.4.4 Reimbursement Scenario
    • 7.4.4.5 India Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.5 Australia
    • 7.4.5.1 Key Country Dynamics
    • 7.4.5.2 Competitive Scenario
    • 7.4.5.3 Regulatory Framework
    • 7.4.5.4 Reimbursement Scenario
    • 7.4.5.5 Australia Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.6 South Korea
    • 7.4.6.1 Key Country Dynamics
    • 7.4.6.2 Competitive Scenario
    • 7.4.6.3 Regulatory Framework
    • 7.4.6.4 Reimbursement Scenario
    • 7.4.6.5 South Korea Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.7 Thailand
    • 7.4.7.1 Key Country Dynamics
    • 7.4.7.2 Competitive Scenario
    • 7.4.7.3 Regulatory Framework
    • 7.4.7.4 Reimbursement Scenario
    • 7.4.7.5 Thailand Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.5 Latin America
  • 7.5.1 Latin America Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2 Brazil
    • 7.5.2.1 Key Country Dynamics
    • 7.5.2.2 Competitive Scenario
    • 7.5.2.3 Regulatory Framework
    • 7.5.2.4 Reimbursement Scenario
    • 7.5.2.5 Brazil Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3 Mexico
    • 7.5.3.1 Key Country Dynamics
    • 7.5.3.2 Competitive Scenario
    • 7.5.3.3 Regulatory Framework
    • 7.5.3.4 Reimbursement Scenario
    • 7.5.3.5 Mexico Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4 Argentina
    • 7.5.4.1 Key Country Dynamics
    • 7.5.4.2 Competitive Scenario
    • 7.5.4.3 Regulatory Framework
    • 7.5.4.4 Reimbursement Scenario
    • 7.5.4.5 Argentina Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.6 Middle East & Africa
  • 7.6.1 Middle East & Africa Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2 South Africa
    • 7.6.2.1 Key Country Dynamics
    • 7.6.2.2 Competitive Scenario
    • 7.6.2.3 Regulatory Framework
    • 7.6.2.4 Reimbursement Scenario
    • 7.6.2.5 South Africa Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3 Saudi Arabia
    • 7.6.3.1 Key Country Dynamics
    • 7.6.3.2 Competitive Scenario
    • 7.6.3.3 Regulatory Framework
    • 7.6.3.4 Reimbursement Scenario
    • 7.6.3.5 Saudi Arabia Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4 UAE
    • 7.6.4.1 Key Country Dynamics
    • 7.6.4.2 Competitive Scenario
    • 7.6.4.3 Regulatory Framework
    • 7.6.4.4 Reimbursement Scenario
    • 7.6.4.5 UAE Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5 Kuwait
    • 7.6.5.1 Key Country Dynamics
    • 7.6.5.2 Competitive Scenario
    • 7.6.5.3 Regulatory Framework
    • 7.6.5.4 Reimbursement Scenario
    • 7.6.5.5 Kuwait Diabetic Foot Ulcer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Competitive Analysis

• 8.1 Company Categorization
• 8.2 Participants' Overview
• 8.3 Financial Performance
• 8.4 Product Benchmarking
• 8.5 Company Market Share Analysis, 2023
• 8.6 Company Market Position Analysis
• 8.7 Strategy Mapping
  • 8.7.1 Mergers & Acquisitions
  • 8.7.2 New Product Launch
  • 8.7.3 Partnerships & Collaborations
  • 8.7.4 Expansion
  • 8.7.5 Others
• 8.8 Company Profiles
  • 8.8.1 ConvaTec, Group Plc
    • 8.8.1.1 Company overview
    • 8.8.1.2 Finacial performance
    • 8.8.1.3 Product benchmarking
    • 8.8.1.4 Strategic initiatives
  • 8.8.2 Acelity L.P., Inc.
    • 8.8.2.1 Company overview
    • 8.8.2.2 Finacial performance
    • 8.8.2.3 Product benchmarking
    • 8.8.2.4 Strategic initiatives
  • 8.8.3 3M Health Care
    • 8.8.3.1 Company overview
    • 8.8.3.2 Finacial performance
    • 8.8.3.3 Product benchmarking
    • 8.8.3.4 Strategic initiatives
  • 8.8.4 Coloplast Corp.
    • 8.8.4.1 Company overview
    • 8.8.4.2 Finacial performance
    • 8.8.4.3 Product benchmarking
    • 8.8.4.4 Strategic initiatives
  • 8.8.5 Smith & Nephew Plc
    • 8.8.5.1 Company overview
    • 8.8.5.2 Finacial performance
    • 8.8.5.3 Product benchmarking
    • 8.8.5.4 Strategic initiatives
  • 8.8.6 B. Braun Melsungen AG
    • 8.8.6.1 Company overview
    • 8.8.6.2 Finacial performance
    • 8.8.6.3 Product benchmarking
    • 8.8.6.4 Strategic initiatives
  • 8.8.7 Medline Industries, LP.
    • 8.8.7.1 Company overview
    • 8.8.7.2 Finacial performance
    • 8.8.7.3 Product benchmarking
    • 8.8.7.4 Strategic initiatives
  • 8.8.8 Molnlycke Health Care AB
    • 8.8.8.1 Company overview
    • 8.8.8.2 Finacial performance
    • 8.8.8.3 Product benchmarking
    • 8.8.8.4 Strategic initiatives
  • 8.8.9 Medtronic Plc
    • 8.8.9.1 Company overview
    • 8.8.9.2 Finacial performance
    • 8.8.9.3 Product benchmarking
    • 8.8.9.4 Strategic initiatives

Chapter 9 Analyst Perspective

관련자료